Podcasts about treated

Dani used to work at the Parkville Youth Justice Precinct and spoke about how well offenders are treated when remanded. See omnystudio.com/listener for privacy information.

Why Your Workouts and Diet Aren't Working: Unlocking the Hidden Hormonal Blocks Are you doing “everything right” for weight loss—eating clean, exercising daily, cutting carbs—and still not seeing results? If you're stuck in weight loss resistance, battling fatigue, bloating, brain fog, and hormonal shifts, this episode is for you. I sat down with hormone fitness and nutrition expert Jenny Swisher to unpack why women in perimenopause and beyond often hit a wall with their metabolism, energy, and gut health despite their best efforts. We explore how chronic stress, adrenal fatigue, and outdated fitness advice can actually sabotage your hormones—and what it really takes to break free from the cycle. Here's what you'll discover in this episode: The hidden connection between overexercising, cortisol, and stubborn belly fat—and why doing more cardio might be working against you. A subtle hormone shift that could explain your energy crashes and weight gain in perimenopause (and what to focus on instead). The #1 nutrition mistake most women make that leads to cravings, low energy, and blood sugar rollercoasters. This episode is packed with practical insights for reclaiming your metabolism, balancing your hormones, and finally getting the results your hard work deserves. If you've ever wondered why your body isn't responding the way it used to—or you feel like you're stuck in survival mode—this conversation will shift the way you think about your health. Listen now to get the clarity (and strategy) you've been missing. How to reach Jenny: https://jennyswisher.com/ Connect with Dr. Meg: Stop wasting time (and money) on products that don't work. My Trusted Brands Guide is the exact list I share with my private clients — the skincare, supplements, food, and wellness tools that have been tested and proven to deliver results. No fluff. No guesswork. Just the brands you can finally feel good about using. ✨ Plus, I scored exclusive discounts from some of these companies just for my community.

Join T, Father Fortenberry, Gary, Marty and Brother Fortenberry as they discuss headlines of the day!Check out our Website:https://lifefromthepatio.com/merchBecome a Legend today:https://thebourbonlegends.comfollow us on TikTok: https://tiktok.com/lifefromthepatio2 @Fatherfortenberry@LFTP@BourbonNerd-LFTP@BrotherFortenberry#bourbon #whiskey #fye #KnobCreek#Jack Daniels#comedy #podcast#funnyvideo #buffalotrace #distillery#buffalo #LFTP#oldforester #jimbeam #heavenhill#Bluenote#Shortbarrel#rye #ark #arknights#arkansas #nba #nfl #razorbacks #newyears #resolutions#LFTP #Fred Minnick#bourbonlive#live#livenews

Hey what's up hello! This week we talk about how people who are in relationships are treated differently than single people. It's like couple privledge but for the individual. We hate it!Donate: patreon.com/soundsfakepod  Follow: @soundsfakepod    Join: https://discord.gg/W7VBHMt  www.soundsfakepod.comBuy our book: www.soundsfakepod.com/book

Dive into Bonus Episode 46 of The Alan Sanders Show, where we unpack the Senate's handling of RFK, Jr.'s nomination, analyzing its implications for public health and political discourse. We break down the heated McEnany vs. Tarlov debate, exploring their clashing perspectives on key issues. The episode also tackles the controversial "defund the police" movement, examining its impact on communities and law enforcement. We discuss the latest developments in the Cook defense case, shedding light on legal strategies and outcomes. Finally, we explore the Tina Peters controversy, delving into election integrity and accountability. Alan delivers unfiltered insights, expert commentary, and thought-provoking discussions on today's most pressing topics. Don't miss this deep dive into politics, justice, and societal change! Please take a moment to rate and review the show and then share the episode on social media. You can find me on Facebook, X, Instagram, GETTR,  TRUTH Social and YouTube by searching for The Alan Sanders Show. And, consider becoming a sponsor of the show by visiting my Patreon page!

Leila Rahimi, Marshall Harris & Mark Grote discuss if Caleb Williams gets treated fairly in the National media and fans in the city.

In this teaching, Jesus challenges us to do something we sometimes don't want to do. Treat others the way we would like to be treated. This even includes those who might have not treated us the best. Everything about this can and does rub us wrong. But Jesus said it and we are supposed to live it. This Sunday we will take a look at this challenging truth from the Creator of the Universe. ———————————————————————————————Gather your church essentials here for notes, prayer, events, etc:https://nbcc.com/church-essentialsConnect with us on Social Media:Instagram: instagram.com/nbccnorcoTikTok: tiktok.com/@nbccnorcoFacebook: facebook.com/nbccnorcoYouTube Channel: https://www.youtube.com/channel/UC6S-3n9PVnXm8zSPHAYVyGwWebsite: https://www.nbcc.com/----------------------------------------If you have any prayer requests or questions, please message us on our social media or send us an email at nbcc@nbcc.com. Don't forget to rate and subscribe to the podcast!----------------------------------------Join us in person, Sunday's at 8:30am, 10am, & 11:30amhttps://goo.gl/maps/PEe1rzXWKBv

After her date with Jay, Tiffany's ready to be exclusive. Colt and Cortney get closer. Chantel's date with Rocky shows her where her heart belongs. Rob and Jeniffer plan their future, while Carlo has something he needs to confess.If you are interested in partaking in Pink Salt Wall's products, please use this link to support them as well as the podcast: https://www.pinksaltwall.com/?ref=TANYKATHOMASPlease rate and subscribe to our podcast. You can rate us at either Apple Podcasts, https://podcasts.apple.com/us/podcast/realitea-times-two/id1689517536 or spotify, https://open.spotify.com/show/7rInYf1BD8YiFeCeOOx8gI. I will also start reading your 4 or 5-star ratings on the air!Patreon is here!!! Go join the Patreon at https://patreon.com/RealiteaTimesTwo?If you like us, please share with your friends.Please visit and follow us on:Facebook: https://facebook.com/realiteatimestwoIG: https://instagram.com/realiteatimestwoThreads: https://www.threads.net/@realiteatimestwoTwitter/X: https://twitter.com/RealiteaxTwoPod Tik Tok: https://www.tiktok.com/@realiteaxtwopod?lang=en Bluesky: https://bsky.app/profile/realiteatimestwo.bsky.social You can also e-mail us at realiteaxtwo@hotmail.com. You can find us on Youtube at https://www.youtube.com/@realiteatimestwoFollow us on Reddit at https://www.reddit.com/r/realiteatimestwopod/ I got a new website!!!! Visit https://realiteatimestwo.podcastpage.io/?v=zzea Listen to my new podcast with my friend Mikel called "Next Take Podcast" at the below YouTube link at: www.youtube.com/@NextTakePodcast/featured Hosted on Acast. See acast.com/privacy for more information.

Hey my wonderful sweet babies, Follow Me:Instagram- fabvictoria94Twitter- VictoriaB_94Snapchat- fabvictoria94TikTok: FabVictoria94Facebook: Victoria BishopFacebook Page- Fabulous Victoria BroadcastsPatreon: Fabulous Victoria PodcastPodcast Name- Fabulous Victoria PodcastYouTube Main Channel: Fabulous VictoriaCashApp: $fabvictoria (optional)Music from Simply Kee Simone, Dessie Style, and Kaysie Amya on YouTube.Email me for business inquiries only:bishopvictoria94@gmail.comTHIS VIDEO IS NOT SPONSORED.

What would change if you gave your business the same care, clarity, and strategy you give your clients? In this episode, technology strategist Stephanie Nelson shares how everything shifted when she started treating herself like her own client. This conversation might just change how you run your business. --- When you're ready to break through to the next revenue level in your consulting business, here are three ways I can help you. 1. Connect with me on LinkedIn for weekly insights on landing better clients and charging for the value you deliver. 2. Get your copy of my Referrals on Repeat guide, and learn five strategies you can implement straight away to take control of the referral process and attract more of the right inquiries – no more sitting around hoping they'll happen. Get your free copy at smartgetspaid.com/referrals 3. Build a repeatable sales and marketing system that gets you better clients, better rates, and less stress in your consulting business. If you're ready to stop leaving your success to chance, learn the proven system women consultants are using to attract ideal clients consistently and get paid for their value. Plus, you'll get help from me and my team every step of the way. If you've been in business for at least two years, you're making at least $120k, and you want to implement a system that's designed specifically for B2B consulting businesses, email team@smartgetspaid.com with "BREAKTHROUGH" in the subject line and I'll get you the details.  

1 + 2 Thessalonians - When You're Treated Unfairly by Velocity Church

Eye specialists say some Kiwis are at risk of going blind, because they're not getting access to the care they need to treat one of the most common causes of vision loss.

Linda Sheehan, patient and Professor Cormac McCarthy, Consultant Respiratory Physician at SVUH and Associate Professor at UCD

In hour four, after leaving the show for a few hours to help his son at physical therapy, Hoch returns with some regret for how he ripped Solana after his ACL surgery a few years ago. Crowder still thinks Solana was just being soft. Chris Grier doesn't rule out a Christian Wilkins return. Plus, some Flanigan's love.

In this episode you will uncover the needs both women and men have to feel fulfilled in relationships. How a Woman can go from chasing after, and begging for the bare minimum. And your a Man will finally have respect for you in your relationship.The Dreamy Girl Academy - The GLOW UP Membership - ⁠⁠⁠⁠Join Here⁠⁠⁠⁠ THE Confident AF Woman PLAN - The Next Level Relationship Transformation- ⁠Enrol Here⁠ Free Masterclass - From Anxiously Attached into High Value Love MAGNET - ⁠Sign Up Here⁠1:1 Client Packages - ⁠Enrol Here THAT WOMAN (is confident AF) AFFIRMATIONS - ⁠⁠⁠⁠Buy Here

Oti Region has recorded 10,233 confirmed cases of typhoid fever in the first half of 2025, sparking serious public health concerns. According to the Regional Health Directorate, the surge underscores the urgent need for improved sanitation and hygiene, as the disease continues to spread through contaminated food and water

Dr. Ben sat down with Dr. Michael Golenhofen to discuss why many doctors miss the real cause of tinnitus. Learn how evidence-based, subtype-specific care can help patients find relief.Get started with Treble Health:Schedule a complimentary telehealth consultation: treble.health/free-telehealth-consultation Take the tinnitus quiz: https://treble.health/tinnitus-quiz-1Download the Ultimate Tinnitus Guide: 2024 Edition: https://treble.health/tinnitus-guide-2024

Bickley and Marotta talk Diamondbacks, go through Rush Hour Reboot, we're joined by Derrick Hall, and the Give-a-Thon for PCH.

Drs Joseph Mikhael and Saad Usmani discuss why quadruplet therapy is now the new standard of care for treating newly diagnosed multiple myeloma patients. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002714. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/38084760/ Isatuximab, Lenalidomide, Dexamethasone and Bortezomib in Transplant-Ineligible Multiple Myeloma: The Randomized Phase 3 BENEFIT Trial https://pubmed.ncbi.nlm.nih.gov/38830994/ Daratumumab Plus Bortezomib, Lenalidomide and Dexamethasone for Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma: The Randomized Phase 3 CEPHEUS Trial https://pubmed.ncbi.nlm.nih.gov/39910273/ Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/38832972/ A Phase 2 Study of Modified Lenalidomide, Bortezomib and Dexamethasone in Transplant-Ineligible Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/29740809/ Bortezomib With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone in Patients With Newly Diagnosed Myeloma Without Intent for Immediate Autologous Stem-Cell Transplant (SWOG S0777): A Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/28017406/ Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial https://pubmed.ncbi.nlm.nih.gov/32325490/ Carfilzomib Induction, Consolidation, and Maintenance With or Without Autologous Stem-Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: Pre-Planned Cytogenetic Subgroup Analysis of the Randomised, Phase 2 FORTE Trial https://pubmed.ncbi.nlm.nih.gov/36528035/ Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients https://www.sciencedirect.com/science/article/abs/pii/S0006497123735416

JCO PO author Dr. Alison M. Schram at Memorial Sloan Kettering Cancer Center shares insights into her JCO PO article, “Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors.” Host Dr. Rafeh Naqash and Dr. Schram discuss relevant genomic and clinical features of patients with BRCA-altered uterine sarcoma and the efficacy of PARPis in this population. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and associate professor at the OU Health Stephenson Cancer Center. Today, we are excited to be joined by Dr. Alison Schram, Associate Attending Physician and Section Head of Oral Therapeutics with Early Drug Development and Gynecologic Medical Oncology Services at the Memorial Sloan Kettering Cancer Center, and the senior author of the JCO Precision Oncology article titled, "Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors." At the time of this recording, our guest's disclosures will be linked in the transcript. Dr. Schram, thank you for joining us today. I am excited to be discussing this very interesting, unique topic based on what you published in JCO PO. Dr. Alison Schram: Thank you for having me. Dr. Rafeh Naqash: What we like to do for these podcasts is try to make them scientifically interesting but at the same time, keep them at a level where our trainees and other community oncology professionals understand the implications of what you've published. So I'd like to start by asking you, what is leiomyosarcoma for those of us who don't necessarily know a lot about leiomyosarcoma, and what are some of the treatment options for these uterine sarcomas? Dr. Alison Schram: Uterine leiomyosarcoma is a rare subtype of uterine cancer, and it represents about 1% of all female cancers in the reproductive tract. This is a rare malignancy that arises from the myometrial lining of the uterus, and it is generally pretty aggressive. In terms of the standard therapy, the standard therapy for uterine leiomyosarcoma includes chemotherapy, generally combination chemotherapy, but despite a few regimens that tend to be effective, the duration of effectiveness is relatively short-lived, and patients with advanced uterine leiomyosarcoma eventually progress and require additional therapy. I will say that localized uterine leiomyosarcoma can be treated with surgery as well. Dr. Rafeh Naqash: Thank you for that description. Now, there are two aspects to what you published. One is the sarcoma aspect, the leiomyosarcoma, and the second is the BRCA mutation. Since we are a precision medicine journal, although we've discussed BRCA a couple of times before, but again, for the sake of our listeners, could you highlight some of the aspects of BRCA and PARP sensitivity for us? Dr. Alison Schram: Yes. So BRCA is a gene that's important for DNA repair, and BRCA mutations can be either inherited as a germline mutation, so one of your parents likely had a BRCA mutation and you inherited one copy. In patients who have an inherited BRCA mutation, the normal cells tend to have one abnormal copy of BRCA, but if a second copy in the cell becomes altered, then that develops into cancer. And so these patients are at increased risk of developing cancers. Specifically, they are at an increased risk of developing ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and a few others. These cancers are considered BRCA-associated tumors. Alternatively, some patients, more rarely, can develop BRCA-altered cancers completely sporadically. So it's a mutation that happens in the tumor itself, and that can lead to impaired DNA repair and promote cancer progression. And those patients are not, they don't have any inherited risk, but just a random event caused a BRCA mutation in the tumor. The reason this is important is because, in addition to it being potentially important for family members, there are certain treatments that are more effective in BRCA-altered cancers. And the main example is PARP inhibitors, which are small molecule inhibitors that inhibit the PARP enzyme, and there is what we call synthetic lethality. So PARP is important for DNA repair, for single-stranded DNA repair, BRCA is important for double-stranded DNA repair, and in a patient that has a cancer that has a BRCA mutation, that cancer becomes more reliant on single-stranded DNA repair. And if you inhibit it with a PARP inhibitor, the cancer cells are unable to repair DNA, and the cells die. So we call that synthetic lethality. PARP inhibitors are FDA approved in several diseases, predominantly the BRCA-associated diseases I mentioned: breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer. Dr. Rafeh Naqash: That was very beautifully explained. Honestly, I've heard many people explain BRCA before, but you kind of put it in a very simple, easy to understand format. You mentioned this earlier describing germline or hereditary BRCA and somatic BRCA. And from what I gather, you had a predominant population of somatic BRCA, but a couple of germline BRCA as well in your patient population, which we'll go into details as we understand the study. You mentioned the second hit on the germline BRCA that is required for the other copy of the gene to be altered. In your clinical experience, have you seen outside of the study that you published, a difference in the sensitivity of PARP for germline BRCA versus a somatic BRCA that has loss of both alleles? Dr. Alison Schram: So we will get into what's unique about uterine sarcomas in just a minute. In uterine sarcomas, what we have found is that the BRCA mutations tend to be somatic and not germline, as you mentioned. That is in contrast to the other diseases we mentioned, where the vast majority of these tumors are in patients that have germline BRCA alterations. So one thing that's really unique about the uterine sarcoma population and our paper, I believe, is that it is demonstrating an indication for PARP inhibitors in a population that is not characterized by germline BRCA alterations, but truly these by somatic BRCA alterations. If you look at the diseases that PARP inhibitors are validated to be effective in, including the, you know, the ones I mentioned, the BRCA-associated tumors, there's some data in specific context that suggests that perhaps germline alterations are more sensitive to PARP inhibitors, but that's not universal, and it's really tricky to do because the genetic testing that we have doesn't always tell you if you have two hits or just one hit. So you need more complex genetic analysis to truly understand if there is what we call a biallelic loss. And sometimes it's not a second mutation in BRCA. Sometimes it's silencing of the gene by hypermethylation or epigenetics. Some of our clinical trials are now incorporating this data collection to really understand if biallelic loss that we can identify on more complex genetic testing predicts for better outcomes. And we think it's probably true that the patients that have biallelic loss, whether it be germline or somatic biallelic loss, are more likely to benefit from these treatments. That still needs to be tested in a larger cohort of patients prospectively. Dr. Rafeh Naqash: In your clinical experience, I know you predominantly use MSK-IMPACT, but maybe you've perhaps used some other NGS platforms, next-generation sequencing platforms. Have you noticed that these reports for BRCA alterations the report mentioning biallelic loss in certain cases? I personally don't- I do lung cancer, I do early-phase lung cancer as well, but I personally don't actually remember if I've seen a report that actually says biallelic loss. So after this podcast, I'm going to check some of those NGS reports and make sure I look at it. But have you seen it, or what would be a learning point for the listeners there? Dr. Alison Schram: Exactly. And they usually do not. They usually do not explicitly say, “This looks like biallelic loss,” on the reports. The exception would be if there's a deep deletion, then that implies both copies of the gene have been deleted, and so then you can assume that it's a biallelic loss. But oftentimes, when you see a frameshift alteration or a mutation, you don't know whether or not it's a biallelic loss. And you may be able to get some clues based on the variant allele frequencies, but due to things like whole genome duplication or more complex tumor genomics, it's not clear from these reports, and you really do need a more in-depth bioinformatic analysis to understand whether these are biallelic or not. So that is why I suggest that this really needs to be done in the context of a clinical trial, but there is definitely a theoretical rationale for reporting and treating patients with biallelic losses perhaps more so than someone who has a variant of unknown significance that seems to be monoallelic. The other tricky part, as I mentioned, is the fact that there could be epigenetic changes that silence the second copy, so that wouldn't be necessarily evident on a DNA report, and you would need more complex molecular testing to understand that as well. Dr. Rafeh Naqash: Sure. Now, going to your study, could you tell us what prompted the study, what was the patient population that you collected, and how did you go about this research study design? Dr. Alison Schram: It's actually a great story. I was the principal investigator for a clinical trial enrolling patients regardless of their tumor type to a combination of a PARP inhibitor and immunotherapy. And this was a large clinical trial that was being done as a basket study, as I mentioned, for patients that have either germline or somatic alterations with advanced solid tumors that had progressed on standard therapy. And the hypothesis was that the combination of a PARP inhibitor and immunotherapy would be synergistic and that there would be increased efficacy compared to either agent alone and that patients who had BRCA alterations were a sensitive population to test because of their inherent sensitivity to PARP inhibitors and perhaps their increased neoantigen burden from having loss of DNA repair. So this large study, it's been published, really did show that there was efficacy across several tumor types, but it didn't seem to clearly demonstrate synergy between the immunotherapy and the PARP inhibitor as compared to what you might expect from a PARP inhibitor alone, and in addition to a couple of cases, perhaps attributable to the immunotherapy. So maybe additive rather than synergistic efficacy. However, what really struck me looking at the data was that there were three patients with uterine leiomyosarcoma with BRCA deletions who had the best responses of anyone on the study. So incredible, durable responses. One of my patients with a complete response that continues to not have any evidence of cancer eight years after the initiation of this regimen. And for those of us that treat uterine leiomyosarcoma, this is unheard of. These patients generally, as I mentioned, respond, if they do respond to chemotherapy, it's generally short-lived and the cancer progresses. And so a complete response nearly a decade later turns heads in this field. The other interesting thing was that these uterine leiomyosarcoma patients had somatic alterations rather than a germline alteration with a second hit, and the diseases that are best validated for being responsive to PARP inhibitors include the BRCA-associated diseases, the ones that you're at increased risk for if you have a germline BRCA mutation, including breast, pancreas, prostate, and ovarian. And so it was very interesting that this disease type that seemed to be uniquely sensitive to PARP inhibitors with immunotherapy was also different in that patients with uterine leiomyosarcoma don't tend to have a high frequency of BRCA alterations, and in patients that are born with a BRCA alteration, there doesn't seem to be a clearly increased risk of uterine sarcomas. So this population really jumped out as a uniquely sensitive population that differed from the prior indications for PARP inhibitors. Given this patient and these couple of patients that we observed on the combination, in addition to some other case reports and case series that had started to come out in small numbers, we wanted to look back at our large cohort of patients at Memorial Sloan Kettering to see if we could really get a better sense of the numbers. How many patients at Sloan Kettering with uterine sarcomas have BRCA alterations? Are they generally somatic or germline? Are there unique features about these patients in terms of their clinical characteristics? How many of them have received PARP inhibitors, and if so, is this just luck that these three patients did so well, or is this really a good treatment option for patients with BRCA-altered uterine sarcomas? And so we did this retrospective analysis identifying the patients at Sloan Kettering who met these criteria. So in total, we found 35 patients with uterine sarcomas harboring BRCA alterations, and the majority were leiomyosarcoma, about 86% of them had leiomyosarcoma, which is interesting because there are other uterine sarcomas, but it does seem like BRCA alterations tend to be more often in the leiomyosarcomas. And 13 of these patients with uterine leiomyosarcoma were treated with PARP inhibitors in the recurrent or metastatic setting with about half of those patients having an overall response, so that's a significant tumor shrinkage that sustained, and a clinical benefit rate of 62%. And if we look at the patients that had these BRCA2 deep deletions, which was the patient I had that had this amazing response, the overall response rate jumped to 60% and the clinical benefit rate to 80%. And we defined clinical benefit rate as having maintained on the PARP inhibitor without evidence of progression at six months. So this is really impressive for patients with a difficult to treat disease. And we couldn't do a randomized controlled trial comparing it to chemotherapy, but looking retrospectively at outcomes on chemotherapy studies, this was very favorable, particularly because many of these patients were heavily pretreated. So to get a sense of, you know, how this might compare to chemotherapy, we tried to use patients as their own internal controls, and we looked at how long patients were maintained on the PARP inhibitor as compared to how long they were on the treatment just prior. And we used a ratio of 1.3 to say if they were on the PARP inhibitor for 1.3 times what their previous treatment was or longer, that is pretty clearly better, more of a benefit from that regimen. And the majority of patients did meet that bar. So 58% had a PFS ratio greater than 1.3, and the average PFS ratio was 1.9, suggesting, you know, you would expect the the later lines of therapy to actually not work as well, but this suggests that it's actually working better than the immediately prior line of therapy, to me, suggesting that this is truly a good treatment option for these patients. Dr. Rafeh Naqash: Very interesting. And you mentioned that individuals with tumors having deep deletions were probably more responsive. How did you figure out that there was biallelic loss or deep deletions? Was that part of an extended analysis that was done subsequently? Dr. Alison Schram: So the deletions reported on our report, if it's a biallelic deletion, that is the one biallelic molecular alteration that would be reported. So those are, by definition, biallelic, and I think that that may be one of the reasons that's a good biomarker. But also, what's interesting is that if you have both copies deleted of BRCA, you can't develop reversion mutations. So one of the the known mechanisms of resistance to PARP inhibitors in patients who have BRCA alterations are something called a reversion mutation where, if you have a frameshift alteration, for example, in BRCA that makes BRCA protein nonfunctional, you can develop a second mutation that actually puts the DNA back in frame, and a functional protein is now made. And so a mechanism of resistance to PARP inhibitors is actually reverting BRCA to a wild-type protein, and then BRCA's synthetic lethality no longer makes sense and is no longer effective. But if you've deleted both copies of BRCA, you don't have the ability to restore the function, and you can't develop reversion mutations. And that's perhaps why, you know, my patient and others have had these prolonged responses to PARP inhibitors because you don't have the same ability to develop that mechanism of resistance. Dr. Rafeh Naqash: I remember thinking a year and a half back, I had an individual with prostate cancer and with BRCA2, and using liquid biopsy, I had a reversion mutation that we caught. In your practice, have you seen the utility of doing the serial liquid biopsies in these individuals to catch these reversion mutations? Dr. Alison Schram: Yes, absolutely. And in patients that have the ability to develop a reversion mutation, serial cell-free DNA can catch it, but the caveat is that it doesn't always. So if you see an acquired reversion mutation in cell-free DNA, that can be helpful, particularly if you're planning on putting the patient on another line of therapy that might require a dysfunctional BRCA. So if you're putting them on a clinical trial with a PARP combination and the rationale is that they're sensitive because they don't have a functional BRCA, you would want to know if they developed a reversion mutation, and serial cell-free DNA can definitely identify these reversion mutations. Some of the major clinical trials in ovarian cancer have done serial cell-free DNA and have demonstrated the utility of that approach. The caveat is that some of these reversion mutations are not readily caught on cell-free DNA because they're more complex reversion mutations, or they're not, the part of the gene that develops the reversion mutation is not tiled on the panel. And so it doesn't always catch the reversion mutations. Also, depends on the cell-free DNA shedding, depends on the tumor volume and other factors. And we published a related paper of a patient, it was a really interesting case of a patient with prostate cancer who was on a PARP inhibitor and developed what appeared to be a single reversion mutation on one sample, had negative cell-free DNA, single reversion mutation in a tissue biopsy, and then developed disease progression. And we did an autopsy, and the patient kindly consented to an autopsy, and at the time of autopsy, there were 10 unique reversion mutations identified across 11 metastases. So almost each metastasis had a unique reversion mutation, and only one of them had been seen premortem on a tissue biopsy and not on a cell-free DNA. But that autopsy really drove home to me how much we're missing by doing clinical testing in real time and we really don't know the entire genomic complexity of our patients by doing single samples. And theoretically, cell-free DNA can catch DNA from all the metastases, so you might think that that would be a solution, and it definitely can catch reversion mutations that are not seen in a single biopsy, but you really need to do it all. I mean, you need to do the tissue biopsy sampling, you need to do cell-free DNA, and probably one cell-free DNA test is not enough. Dr. Rafeh Naqash: Thank you, again, for that very nice explanation. Now, one quick provocative question. I remember when I was training, the lab that I used to work in, they used to do a lot of phosphorylation markers for DNA damage response, like phospho NBS, RAD51. Have you seen anything of that sort on these biallelic BRCA mutations where tumors are responding, but they also have a very high signature on the phosphorylation side, and it may or may not necessarily correspond to HRD signatures, but have you noticed or done any of that analysis? Dr. Alison Schram: I think that it would be great to do that analysis. And some of the work we're doing now is actually trying to dig a little bit deeper in our cohort of patients to understand are these HRD-positive tumors? Does HRD positivity correlate with response to BRCA alterations? In terms of the functional assays, I would love to be able to do a functional assay in these samples. One of the challenges is that this was a retrospective study and many of the patients were previously treated as standard of care or off-label with these agents, and so we didn't have prospective tissue collection, and so we're really limited by the tissue that was collected as part of standard of care and the consent forms that the patient signed that allow us to do genomic and molecular testing on their samples. So, I think that is hopefully future work that we will do and others will do. Dr. Rafeh Naqash: Sure. Shifting gears to your career trajectory, I'd like to spend a couple of minutes there before we end the podcast. So Dr. Schram, you've obviously been a trailblazer in this space of drug development, early-phase trials. Can you give us a brief synopsis of your journey and how you've successfully done what you're doing and what are some of the things that drive you? Dr. Alison Schram: Well, thank you for saying that. I don't know if that's true, but I'll take the bait. I've been interested in oncology since college and was always very interested in not only the science of oncology but of course, treating patients. And in medical school, I did basic science research in a laboratory and it was very inspiring and made me want to do research in oncology in addition to clinical care. When I became an oncology fellow, I was presented with a very difficult question, which is, “Do you want to be a lab PI and be in the lab, or do you want to do clinical care and clinical research?” And I couldn't choose. I found a mentor who thankfully really had this amazing vision of combining the two and doing very early drug development, taking the data that was being generated by labs and translating it into patients at the earliest stage. So, you know, phase one drug development in molecularly targeted therapies. And so I became very interested as a fellow in early drug development and this ability to translate brand new molecular insights into novel drugs. And I joined the- at Sloan Kettering, there was the Early Drug Development, it was actually a clinic, it was called something different, and it was very fortuitous. My last year of fellowship, the clinic became its own service with the ability to hire staff at Sloan Kettering, and I was the first ever hire to our Early Drug Development Service. And that really inspired me to try and bring these drugs to patients and to really translate the amazing molecular insights that my colleagues here at Sloan Kettering are discovering, and you know, of course, at other institutions and in pharma. And you know, there 's been an amazing revolution in in drug development over the last several years, and I feel very grateful that I've been here for it. You know, I've been able to take the brilliant insights from my colleagues and put these drugs in patients, and I have the amazing privilege of watching patients in many cases that benefit from these treatments. And so I do mostly phase one drug development and molecularly targeted therapies, and truthfully, I am just very fortunate to be around such brilliant people and to have both patients and labs trust me to be able to deliver these new drugs to patients and hopefully develop better drugs that move forward through FDA approval and reach patients across the country. Dr. Rafeh Naqash: Thank you so much. That was very nicely put. And hopefully our trainees and junior faculty find that useful based on their own career trajectories. Thank you, Dr. Schram, for joining us today. Hopefully, we'll see more of your subsequent work in JCO PO. Thank you for giving us all these insights today. Dr. Alison Schram: Thank you for having me. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Alison Schram Disclosures Consulting or Advisory Role Company: Mersana, Merus NV, Relay Therapeutics, Schrodinger, PMV Pharma ,Blueprint Medicines, Flagship Pioneering, Redona Therapeutics, Repare Therapeutics, Endeavor BioMedicines Research Funding Company: Recipient: Your Institution  Merus, Kura, Surface Oncology, AstraZeneca, Lilly, Pfizer , Black Diamond Therapeutics, BeiGene, Relay Therapeutics, Revolution Medicines,  Repare Therapeutics, PMV Pharma, Elevation Oncology, Boehringer Ingelheim Travel, Accommodations, Expenses Company: PMV Pharma 

In this week's episode, we'll learn more about how exogenous CD19 stimulation affects CAR T-cell persistence in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy; new algorithms that incorporate sequential rapid immune-assays, intended to improve diagnosis of heparin-induced thrombocytopenia, and resource-adaptive survival prediction models to help guide management of patients with chronic myelomonocytic leukemia.Featured Articles:Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALLSequential combinations of rapid immunoassays for prompt recognition of heparin-induced thrombocytopeniaBLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

COFFEE MOANING the PODCAST ON APPLE PODCASTS: https://podcasts.apple.com/gb/podcast/coffee-moaning/id1689250679ON SPOTIFY: https://open.spotify.com/show/3p6z4A1RbhidO0pnOGGZl2?si=IqwD7REzTwWdwsbn2gzWCg&nd=1HOW TO STAY MARRIED (SO FAR) the PODCASTON SPOTIFY: https://open.spotify.com/show/57MT4cv2c3i06ryQlIpUXc?si=1b5ed24f40c54ebaON APPLE PODCASTS: https://podcasts.apple.com/gb/podcast/how-to-stay-married-so-far/id1294257563 Hosted on Acast. See acast.com/privacy for more information.

✅اپیزود میانی✅⚡️⚡️⚡️در قسمت❌ نوزدهم❌In-Sight در مورد اثر سیگار کشیدن و پریودونتیت درمان شده در ماندگاری و موفقیت ایمپلنت صحبت میکنیمابسترکت مربوط به یکی از مقالات کانسنسوس ITI هست‼️‼️پادکست In-Sight مجموعه ای از پادکستهای کوتاهه که در اون ها ما بدون پرداختن به جزئیات ،خلاصه ی مقالات را مرور میکنیمپادکست In-Sight اپیزود میانی دنتکستهاستدکتر فواد شهابیان متخصص پروتز ،ایمپلنت زیباییاهواز کیانپارس061 3338 0090 Hosted on Acast. See acast.com/privacy for more information.

Are Men Treated Fairly in Domestic Violence Cases?

As we read Jesus' parable about the tenants in the vineyard today (Mark 17 v.1-9) and the treatment they meted out to any servants that came to them on behalf of the owner seeking his share of the fruit, our thoughts went quite naturally to what we had just read in Jeremiah who brought from God messages that did not please the leading men of his day.  All the counsellors of the king saw his words as undermining them, they did not accept his version as to the attitude of God towards them despite the fact that his warnings had so far proved true.They “treated him shamefully” putting him in the waterless cistern so that he sank in the mud at the bottom.  (ch. 38 v.4-6).   It is significant that it is a Gentile, an Ethiopian, that alerts the King to his plight and rescues him (v.7-13); this is parallel to some of the experiences of the apostle Paul..Returning to the parable of Jesus we can see its application not only to how the tenants killed Jesus the son of the owner, but to the treatment through the centuries of those who are faithful to the truths God has left on record in the scriptures. How many cling to their own distorted philosophies and, as Paul complained, “exchanged the truth about God for a lie” [Rom. 1 v.25]Our chapter today tells us how Jesus tackled the Sadducees over this.  They deny there is to be a resurrection. Jesus rebukes them saying you “are wrong, because you know neither the Scriptures nor the power of God” [v.24] He says that those “who rise from the dead, they neither marry nor are given in marriage, but are like angels in heaven.” [v.25]  How vital that we “know … the Scriptures.”On another occasion Jesus said “there will be weeping and gnashing of teeth, when you see Abraham and Isaac and Jacob in the kingdom of God but you yourselves cast out” [Luke 13 v.28] That it is a literal kingdom on earth is made plain in the next verse, “and people will come from east and west, and from north and south, and recline at table in the kingdom of God.”Together with Abraham, Isaac and Jacob will be such as Jeremiah and, most likely, “the scribe” who “answered wisely” – as we read in today's chapter – so that Jesus said to him, “You are not far from the Kingdom of God.” [v.34] We must each ask ourselves, ‘How far am I from the Kingdom of God?'

Hey, it's Amy Newmark with your Chicken Soup for the Soul and we have a new book I'm very passionate about. It's all about how Self-Care Isn't Selfish. That's because self-care is not optional. It's a necessary, powerful commitment to making yourself a priority. And it also means learning how to stick up for yourself. Sometimes we don't do that. We are trying to be nice, or we can't initially believe that someone IS NOT treating us right, so we let it slide, and then it kind of becomes the official way that relationship is going to be. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Charity Prostate Cancer UK says some people are being treated when they don't need to be. Learn about this news story with Phil and Pippa.Find full subtitles and a worksheet for this episode at: https://www.bbc.co.uk/learningenglish/english/features/learning-english-from-the-news_2025/250813FIND BBC LEARNING ENGLISH HERE: Visit our website ✔️ https://www.bbc.co.uk/learningenglish Follow us ✔️ https://www.bbc.co.uk/learningenglish/followusSUBSCRIBE TO OUR NEWSLETTER: ✔️ https://www.bbc.co.uk/learningenglish/newslettersFor more of our podcasts, search for these in your podcast app: ✔️ Learning English for Work ✔️ Learning Easy English ✔️ Learning English Grammar ✔️ Learning English Stories ✔️ 6 Minute English ✔️ Learning English Conversations ✔️ Learning English Vocabulary

In this episode, we hear some of Jesus most powerful teaching, and we are challenged to go out an live it in our day to day lives.

FEATURE Treat People the Way You Want to Be Treated by Mia by 826 Valencia

​​If your energy is constantly drained, the scale won't budge no matter what you try, or your gut feels like it's staging a daily rebellion—your hormones could be the hidden culprit. In this episode, I sit down with functional medicine expert Dr. Betty Murray to unpack how perimenopause, hormone metabolism, and hormone replacement therapy (HRT) play a much bigger role in our health than most of us are told. We get into the real reasons behind chronic fatigue, weight loss resistance, bloating, brain fog, and IBS—and why typical lab tests are missing the mark. This conversation is your backstage pass into what's really going on with your metabolism, your mood, and your midsection—and what to do when “normal” labs still leave you feeling off. What You'll Hear in This Episode: • Why perimenopause symptoms can start up to a decade before menopause—and the subtle hormone shift that might explain your energy crashes • The shocking truth about estrogen and breast cancer risk (spoiler: the data may surprise you) • The real reason your hormones might not be working—even if you're on HRT • How hormone metabolism and detoxification are key to healing gut health and resolving symptoms like bloating and IBS Here's Why You'll Want to Hit Play: Most women are only testing their estradiol levels—and missing the bigger picture. In this conversation, Dr. Murray shares why hormone replacement isn't just about putting hormones in… it's about how your body clears them. She also reveals how factors like gut health, inflammation, and adrenal fatigue influence your entire hormone pathway. We talk about the HPATG axis, how cortisol and stress impact your cycle, and why symptoms like constipation, leaky gut, and low progesterone are often overlooked. Plus, we break down the Dutch test, estrogen dominance, and how the right hormone therapy could transform your energy, cognitive health, and even protect your bones. If you're dealing with: Daily fatigue that coffee can't fix Unexplained weight gain and belly fat Bloating, gas, or IBS symptoms that won't go away Brain fog and memory issues that scare you Mood swings, sleep struggles, or crashing energy... ...this episode will give you the “why” behind it all—so you can finally take the right next step. WellPower is a free health magazine by Dr. Meg Mill, packed with expert insights, in-depth articles, and practical tips on hormone balance, gut health, and metabolic wellness for women in perimenopause and beyond. Get your free copy at https://go.megmill.com/wellpower and start optimizing your health today! Get clarity on your hormones with The Hormone Fixer—a free checklist to help you identify imbalances and take the first steps toward better health. Download now at https://go.megmill.com/hormonefixer. Let's connect on Instagram for daily health tips at @drmegmill. Learn more about how Dr. Meg can help you uplevel your health at www.megmill.com How to reach Dr. Betty: Website: https://www.bettymurray.com/ This content is for educational purposes only and should not be taken as medical advice. Always consult with a healthcare professional before starting any new diet or exercise program. This podcast is for women in perimenopause and beyond who are struggling with fatigue, brain fog, bloating, weight loss resistance, and unpredictable hormones. If you're dealing with exhaustion, low energy, digestive discomfort, or hormone imbalances, you'll learn how to support your metabolism, balance hormones naturally, beat IBS and bloating, and finally break through stubborn weight gain. Discover science-backed strategies to optimize digestion, improve gut health, and manage perimenopause symptoms—without restrictive diets or endless supplements. Whether it's addressing estrogen dominance, blood sugar balance, or adrenal fatigue, this podcast gives you the tools to take control of your health and feel vibrant again. If you are enjoying the show, please subscribe and leave a review or share it with a friend.  If you listen to any of the following shows, we're sure you'll like ours too!  Pursuit of Wellness with Mari Llewellyn, Everyday Wellness with Cynthia Thurlow, Just Ingredients Podcast, Longevity with Nathalie Niddam, Wellness Mama, The Dr. Josh Axe Show, Ancient Health Podcast, The Model Health Show, Grounded Wellness By Primally Pure, Be Well By Kelly Leveque, The Hormone Solution with Karen Martel, The Dr. Hyman Show, The Thyroid Fixer with Dr. Amie Hornaman, Treated with Dr. Sara, Well Beyond 40 with JJ Virgin, Better! with Dr. Stephanie, Energized with Dr. Mariza Snyder  

Send us a text & leave your email address if you want a reply!The Revolutionary Strategic Dating Approach That's Changing Online Dating Forever. Tired of endless swiping with no results? What if finding lasting love was as simple as creating a business plan? In 2025, dating apps are shifting away from mindless matches and toward smarter, more intentional connections, and one marketing expert has cracked the code. Meet Meirav Rosenberg, who applied ruthless business analytics to her dating life and found her husband on date #60 after just six months of strategic dating. In this game-changing episode of Sex Reimagined, discover the dating app optimization secrets that dating apps don't want you to know and why traditional dating advice is failing you.EPISODE HIGHLIGHTSHow to create your "dating business plan" with target audience definitionWhy she wrote a detailed list of partner qualities (including the mysterious "plays an instrument" requirement that proved prophetic)The AB testing approach for dating app photos and profiles that actually worksHow putting her Spotify playlist on her profile became a "key to love her"The profile strategy that attracts quality matches when competition is fierceWhy she never got discouraged during 60 dates (hint: it's about mindset)The breakthrough moment about learning to receive love 2.5 years into her marriageHow to view each date as either teaching or learning—never a waste of timeLINKS & RESOURCES MENTIONED IN THE EPISODE CAN BE FOUND ON THE WEBSITE - CLICK HEREAWAKENING THE GODDESS IN CRETE! Leah & Willow want to take you on an all-woman's tantric pilgrimage to Greece Oct 5-12, 2025! Join us for a trip of lifetime. THE VAGINAL ORGASM MASTERCLASS. Discover how to activate the female Gspot, clitoris, & cervical orgasms. Save 20% Coupon: PODCAST 20 LAST 10x LONGER. If you suffer from premature ejaculation, you are not alone, master 5 techniques to cure this stressful & embarrassing issue once and for all. Save 20% Coupon: PODCAST20. Support the show SxR Website Dr. Willow's Website Leah's Website

Listen to Jacqui's thoughts. See omnystudio.com/listener for privacy information.

Ripley's Believe It Or Not - 1 Minute Episodes xx-xx-xx (261) Book Treated Like a King

FLORIDA FRIDAY - Floridaman beats up a golfer for playing too slowly. Florida woman arrested for posing as a nurse and treating over 4000 patients without a license. Floridaman arrested for stealing Smokey the Bear signs to sell online. Woman arrested for possession of meth at Disney World, Florida. // Weird AF News is the only daily weird news podcast in the world. Weird news 5 days/week and on Friday it's only Floridaman. SUPPORT by joining the Weird AF News Patreon http://patreon.com/weirdafnews - OR buy Jonesy a coffee at http://buymeacoffee.com/funnyjones Buy MERCH: https://weirdafnews.merchmake.com/ - Check out the official website https://WeirdAFnews.com and FOLLOW host Jonesy at http://instagram.com/funnyjones

Autumn Bardisa, 29, is facing multiple fraud charges after authorities say she used another registered nurse's license number to keep her job at an AdventHealth hospital in Palm Coast, Florida. In reality, Bardisa had failed the licensing exam to become an RN. Law&Crime's Jesse Weber explains how Bardisa was able to get away with her alleged scheme for so long and how she got caught with Florida trial attorney Alexis Rosenberg.PLEASE SUPPORT THE SHOW: Stay Informed, Stay Safe – Check Public Records with TruthFinder now at https://www.truthfinder.com/lcsidebarHOST:Jesse Weber: https://twitter.com/jessecordweberLAW&CRIME SIDEBAR PRODUCTION:YouTube Management - Bobby SzokeVideo Editing - Michael Deininger, Christina O'Shea & Jay CruzScript Writing & Producing - Savannah Williamson & Juliana BattagliaGuest Booking - Alyssa Fisher & Diane KayeSocial Media Management - Vanessa BeinSTAY UP-TO-DATE WITH THE LAW&CRIME NETWORK:Watch Law&Crime Network on YouTubeTV: https://bit.ly/3td2e3yWhere To Watch Law&Crime Network: https://bit.ly/3akxLK5Sign Up For Law&Crime's Daily Newsletter: https://bit.ly/LawandCrimeNewsletterRead Fascinating Articles From Law&Crime Network: https://bit.ly/3td2IqoLAW&CRIME NETWORK SOCIAL MEDIA:Instagram: https://www.instagram.com/lawandcrime/Twitter: https://twitter.com/LawCrimeNetworkFacebook: https://www.facebook.com/lawandcrimeTwitch: https://www.twitch.tv/lawandcrimenetworkTikTok: https://www.tiktok.com/@lawandcrimeSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Hydrotreated Vegetable Oil, is a renewable fuel that's made from used cooking oil, plant oils or animal fats internationally, suspicion is mounting that there is rampant fraud in the supply of HVO from Malaysia, Indonesia and China. Prof Hannah Daly, professor of sustainable energy at University College Cork she joined John to tell us more.

#90dayfiance #huntforlove #recapThoughts? Email cbiztvmedia.comcbiztvmedia.com

After her date with Jay, Tiffany's ready to be exclusive. Colt and Cortney get closer. Chantel's date with Rocky shows her where her heart belongs. Rob and Jeniffer plan their future, while Carlo has something he needs to confess Gift the gift of gay! ⁠https://www.patreon.com/RealityGays/gift⁠ JOIN RealityGays+ for exclusive content  + Patreon ⁠ ⁠⁠https://www.patreon.com/RealityGays⁠ or  + Supercast ⁠ ⁠⁠https://realitygaysmulti.supercast.com/⁠  + Apple Subscriptions https://podcasts.apple.com/us/podcast/reality-gays-with-mattie-and-poodle/id1477555097  We covered the latest season of The Secret Lives of Mormon Wives Season 2 on Hulu!  Watch us on video ⁠www.youtube.com/@RealityGays⁠ Click here for all things RG!  ⁠⁠https://linktr.ee/RealityGays⁠ To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Wherein  after her date with Jay, Tiffany's ready to be exclusive. Colt and Cortney get closer. Chantel's date with Rocky shows her where her heart belongs. Rob and Jeniffer plan their future, while Carlo has something he needs to confess.---Please support us by giving us a 5-star review on Apple Podcast, Spotify, Amazon Music or any podcast app of your choice. Patron supporters get EXCLUSIVE content such us a live every first Monday of the month. Follow us! Instagram, X and TikTok: @docusweeties @justcallmewah @Chrislfarah Patreon.com/docusweeties (http://Patreon.com/docusweeties) Join us on our Facebook group!  https://www.facebook.com/groups/6702616296426962Become a supporter of this podcast: https://www.spreaker.com/podcast/docusweeties-with-chris-and-wah--6618122/support.

After their 21 month old daughter Lily was experiencing stomach pains in April of 2024, Nicky and Dan Rankin took her to an Emergency Room and she was then admitted to Children's Hospital at the Anschulz campus in Aurora, Colorado. Shortly after that, Lily was diagnosed with High Risk Neuroblastoma. 16 months later as we enter August of 2025, Lily is doing as well as possible . Dan will discuss what Lily has been through and the Half Triathlon that he has been training for to raise money because of the great treatment that Lily has received at Children's Hospital.

On a recent night in the town of Kerman in Fresno County, hundreds of people gathered at the local football field. They were there for an event that has happened in Kerman only twice before. And it left the community star-struck. Reporter: Samantha Rangel, KVPR California will deploy almost $2 million to prevent thousands of people from losing their health insurance, as White House cuts hit the Affordable Care Act marketplace. Reporter: Carly Severn, KQED Learn more about your ad choices. Visit megaphone.fm/adchoices

6pm: John breaks down the trouble with Trump going after Biden for treason // House Oversight Committee issues subpoena for Ghislaine Maxwell //  Judge denies Justice Department request to unseal Epstein grand jury records // Furious Spirit Airlines passenger lashes out after being banned for her outfit: 'They treated me like a criminal' // This Day in History – 1999 – “Doomed” Woodstock ’99 begins // Now Casting:  Couples in Conflict // Why John’s wife wants to apply for this show

Dr. Dan Ackerman and Dr. James Ernest Siegler discuss the complexities of treating ESUS and emphasize the importance of personalized treatment approaches based on individual patient factors.  Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213876 

The case revolutionized how we treated missing persons cases. But what about how we raised our kids? Hour 1 7/22/2025 full 2122 Tue, 22 Jul 2025 19:00:00 +0000 D5xtUdbcA7xSfigI8OheSep2aeaM5BYF news The Dana & Parks Podcast news The case revolutionized how we treated missing persons cases. But what about how we raised our kids? Hour 1 7/22/2025 You wanted it... Now here it is! Listen to each hour of the Dana & Parks Show whenever and wherever you want! © 2025 Audacy, Inc. News False

Dr. Dan Ackerman talks with Dr. James Ernest Siegler about the complexities of treating ESUS and emphasizes the importance of personalized treatment approaches based on individual patient factors.  Read the related article in Neurology®. Disclosures can be found at Neurology.org. 

NetSuite: Download the free e-book “Navigating Global Trade: 3 Insights for Leaders” at https://www.netsuite.com/ICED ZipRecruiter: Try ZipRecruiter for FREE at https://ziprecruiter.com/ICH ZocDoc: Go to https://www.zocdoc.com/ICED and download the Zocdoc App for FREE Range Rover Sport: Start designing your Range Rover Sport today at https://www.rangerover.com/us/sport MagicMind: Get 60% off the Magic Mind offer here: https://magicmind.com/ichmf #magicmind #mentalwealth #mentalperformancecoach Donate to Tyler Wall's(Coach) GoFundMe - https://www.gofundme.com/f/tyler-the-man-the-myth-the-absolute-legend Follow : Majd Khader and  @MrBeast  On Youtube - https://www.youtube.com/@UCdM2EeG5UH9di5HtmGXK__Q On Instagram - https://www.instagram.com/majdk/?hl=en On X - https://x.com/majdkhader_ Apply for The Index Membership: https://entertheindex.com/ Add us on Instagram: https://www.instagram.com/jlsselby https://www.instagram.com/gpstephan Official Clips Channel: https://www.youtube.com/channel/UCeBQ24VfikOriqSdKtomh0w For sponsorships or business inquiries reach out to: tmatsradio@gmail.com For Podcast Inquiries, please DM @icedcoffeehour on Instagram! Timecodes: 00:00:00 - Intro 00:01:21 - Tax bill & spending plans 00:03:46 - Getting into MrBeast's video 00:04:41 - Meeting MrBeast 00:05:27 - First MrBeast challenge experience 00:08:53 - Reaction to weight loss challenge 00:10:57 - Outside world contact 00:12:13 - When weight gain started 00:13:12 - When weight became a problem 00:16:30 - Mental health changes 00:17:43 - Sponsor - NetSuite 00:18:47 - Caffeine addiction 00:23:41 - Challenge strategy 00:24:39 - His meals during challenge 00:26:46 - Best foods for weight loss 00:27:22 - Hardest part of weight loss 00:29:21 - Lessons from coach 00:33:53 - Advice to others 00:35:30 - Happiness: then vs. now 00:37:38 - Sponsor - ZipRecruiter 00:38:34 - Sponsor - Zocdoc 00:39:48 - Treated differently now? 00:44:21 - Best workouts 00:48:08 - Life after the challenge 00:53:13 - First time watching video 00:58:26 - Post-challenge cheat meals 00:59:29 - New opportunities 01:02:12 - Happier with $500K? 01:03:41 - Sponsor - Range Rover 01:08:03 - Do you miss competing? 01:08:59 - Why obesity is common 01:10:57 - Quitting sugar is hard 01:14:25 - Goals going forward 01:15:57 - Biggest insecurity 01:18:21 - Still in touch with MrBeast? 01:20:22 - Thoughts on Ozempic 01:21:56 - Was this the hardest thing? 01:26:55 - What could've changed you sooner 01:32:11 - Advice for losing weight 01:33:11 - Tips for MrBeast competitors *Some of the links and other products that appear on this video are from companies which Graham Stephan will earn an affiliate commission or referral bonus. Graham Stephan is part of an affiliate network and receives compensation for sending traffic to partner sites. The content in this video is accurate as of the posting date. Some of the offers mentioned may no longer be available. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The best conversations about the Cavaliers from The Ken Carman Show with Anthony Lima, Baskin & Phelps, and the Afternoon Drive during the week of July 14-18. Talking Cavs offseason, looking ahead to the 2025-26 campaign, and looking at LeBron's situation in Los Angeles. Should he put pressure on the Lakers to deal him, and are they treating him with the proper respect given his stature in the game? All that and more.

The best conversations about the Cavaliers from The Ken Carman Show with Anthony Lima, Baskin & Phelps, and the Afternoon Drive during the week of July 14-18. Talking Cavs offseason, looking ahead to the 2025-26 campaign, and looking at LeBron's situation in Los Angeles. Should he put pressure on the Lakers to deal him, and are they treating him with the proper respect given his stature in the game? All that and more.

What do you do when someone wounds you—and you're left with the fallout?Steven Lee shares a raw, personal story of betrayal and loss, wiring nearly all his savings to a scam artist, and how that wound could have shaped his story. But instead of staying stuck in pain or lashing out in revenge, Steven takes us to the cave with David in 1 Samuel 24, where we learn three ways to respond when life wounds us deeply: Resist the Drift, Respond with Honor, and Release the Outcome to God.This message isn't just about being hurt. It's about who we're becoming in the process. Steven walks through the tension of wanting payback vs. choosing restraint, trusting God even when the outcome doesn't make sense, and how God uses our lowest moments to build something stronger in us. When pain tries to define us, faith gives us a better script. You don't have to throw the spear.